Despite the landmark success of PARP inhibitors in breast cancer therapy, the molecular mechanisms underlying resistance—particularly the pro-survival signaling mediated by sphingolipid-metabolic enzyme SPHK1—remain insufficiently understood. The gene discussed is PARP1; the disease is breast carcinoma.